AbbVie's Tepkinly wins EU approval for follicular lymphoma

Tempus announced an expanded, multi-year collaboration with Moderna and Merck to support the potential commercialization of intismeran autogene, also known as V940 or mRNA-4157, a potential first-in-class individualized neoantigen therapy being evaluated in combination with KEYTRUDA in patients with completely resected stage IIB-IV melanoma and other cancer types. Intismeran autogene is jointly developed by Moderna and Merck, known as MSD outside the United States and Canada, and the new collaboration builds on joint efforts initiated last year. Under the agreement, Tempus will manage the timely collection and transfer of tumor tissue and blood samples required for next-generation sequencing, and, subject to applicable regulatory approvals, will also provide NGS services to support the intismeran autogene design and manufacturing process. Financial terms of the collaboration were not disclosed. Moderna Chief Business Officer Said Francis said the partnership lets the company leverage Tempus's commercial footprint and advanced sequencing capabilities, while Jannie Oosthuizen, President of Global Oncology and MSD International, said such collaborations are helping build the infrastructure needed to bring individualized neoantigen therapies to patients at scale.

Genmab posted two fresh oncology trial readouts, including a Phase 3 win for epcoritamab in newly diagnosed diffuse large B cell lymphoma. The EPCORE DLBCL 2 trial, run with AbbVie, reported that epcoritamab plus R CHOP cut the risk of disease progression or death by 51% versus R CHOP alone in patients with higher risk DLBCL. Separately, the Phase 1/2 RAINFOL 01 study of rinatabartsesutecan, or Rina S, in platinum resistant ovarian cancer reported a 45.9% confirmed objective response rate in a heavily pretreated population, with a median duration of response of 12.1 months and no clear safety signals around eye toxicity, peripheral neuropathy, interstitial lung disease or stomatitis. The trial headlines arrive after a strong run in the shares, with the DKK2,482.0 price coming alongside a 31.18% 90 day share price return and a 23.67% year to date share price return, while the 5 year total shareholder return is down 8.75%.

Genmab A/S Sponsored ADR shares rallied 10.7% in the last trading session to close at $38.48, following positive top-line results from the phase III EPCORE DLBCL-2 study. Genmab and its partner AbbVie announced that epcoritamab in combination with R-CHOP demonstrated a statistically significant improvement in progression-free survival in patients with newly diagnosed diffuse large B-cell lymphoma. The company is expected to post quarterly earnings of $0.37 per share in its upcoming report, a year-over-year change of -43.1%, on revenues of $1.18 billion, up 15.7% from the year-ago quarter. The consensus EPS estimate for the quarter has been revised 8.7% higher over the last 30 days, and the stock currently carries a Zacks Rank #3 (Hold).

Orion Corporation, known as Orion Pharma, has entered into an agreement with Qilu Pharma Europe to commercialise an intravenous pembrolizumab biosimilar in Europe. Under the terms, Orion Pharma gains the exclusive right to distribute, market and sell Qilu's IV pembrolizumab biosimilar across Europe, while Qilu will supply the product and receive a share of profits plus certain development, regulatory and sales milestone payments. Pembrolizumab is an immune checkpoint inhibitor used to treat various cancers, and Qilu is currently developing the IV version. Satu Ahomäki, EVP Generics and Consumer Health at Orion Pharma, said the deal expands the company's strategic partnership with Qilu and brings its division closer to its long-term targets and strategic goals. Orion Pharma reported net sales of EUR 1,890 million in 2025 and employs about 4,000 professionals worldwide.

Summit Therapeutics has signed a clinical collaboration with AstraZeneca and its Japan-based partner Daiichi Sankyo to evaluate ivonescimab in combination with the antibody-drug conjugate Datroway, also known as datopotamab deruxtecan, across multiple solid tumors including breast and lung cancers. The collaboration is expected to initially focus on a phase III study in first-line triple-negative breast cancer, expanding ivonescimab's development into a new tumor type. Under the agreement, each company will supply its respective drug, AstraZeneca or Daiichi will sponsor the planned studies, and the companies will share study costs while retaining development and commercial rights to their own therapies. The Datroway collaboration builds on the larger deal between AstraZeneca and Summit announced in the last week, under which AstraZeneca agreed to invest $2 billion in Summit to accelerate development of ivonescimab, with the companies also set to evaluate ivonescimab alongside AstraZeneca's investigational Claudin-18.2-targeted ADC sonesitatug vedotin, or Sone-Ve, in gastrointestinal cancers. An FDA filing is under review seeking approval for ivonescimab plus chemotherapy in patients with EGFR-mutated, locally advanced or metastatic non-squamous NSCLC who had progressed following EGFR-TKI treatment, with a final decision expected by Nov. 14, 2026.